Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Pemetrexed 3mifamurtide 2lenvatinib 2dostarlimab 2belinostat 2Ifosfamide 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gemcitabine 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2vactosertib 1surufatinib 1sintilimab 1robatumumab 1ridaforolimus 1reolysin 1pembrolizumab 1pazopanib 1omburtamab I-131 1niraparib 1isophosphamide mustard 1fludarabine 1endostar protein 1dinutuximab 1copanlisib 1cc-486 1cabozantinib 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Osteosarcoma × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡